Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.35 |
| ▸ | EGFR | P00533 | 8/20 | 0.34 |
| ▸ | CSF1R | P07333 | 4/20 | 0.34 |
| ▸ | KDR | P35968 | 3/20 | 0.32 |
| ▸ | FLT1 | P17948 | 2/20 | 0.32 |
| ▸ | RET | P07949 | 2/20 | 0.32 |
| ▸ | KIF5B | P33176 | 2/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.32 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | BACE2 | Q9Y5Z0 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.31 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.31 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.31 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.31 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.31 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.31 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL833246 | 0.83 | PDPK1 (0.46) | PDPK1MKNK2EGFRAURKB | |
| SCHEMBL28049195 | 0.75 | PDPK1 (0.50) | PDPK1EGFRMAP4K4LMNACYP1A2 | |
| SCHEMBL13210054 | 0.72 | MAP2K4 (0.36) | BACE1BACE2GABRG2GABRB3GABRA5 | |
| SCHEMBL16638904 | 0.70 | SYK (0.36) | PDPK1BACE1BACE2GABRA1GABRG2 | |
| SCHEMBL17362697 | 0.70 | PDPK1 (0.39) | PDPK1MKNK2LMNA | |
| SCHEMBL862727 | 0.70 | GABRG2 (0.33) | GABRG2GABRB3GABRA5 | |
| SCHEMBL21925311 | 0.69 | PDPK1 (0.43) | PDPK1MKNK2IRAK4MAP4K4 | |
| SCHEMBL1586023 | 0.69 | PDPK1 (0.62) | PDPK1MAP4K4LMNACYP1A2CYP3A4 | |
| SCHEMBL1585511 | 0.69 | PDPK1 (0.48) | PDPK1EGFRMAP4K4BACE1BACE2 | |
| SCHEMBL17362811 | 0.69 | PDPK1 (0.40) | PDPK1MKNK2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901139-B2 | Tricyclic indole derivatives and methods of use thereof | MERCK SHARP & DOHME CORP. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8404845-B2 | 2,3-substituted azaindole derivatives for treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8404845-B2 | 2,3-substituted azaindole derivatives for treating viral infections | MERCK SHARP & DOHME CORP. (US) | 2013-03-26 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC | 2011-08-04 | — | — | US | disclosed |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | SHERING CORPORATION | 2011-05-05 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-05-05 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110104109-A1 | TETRACYCLIC INDOLE DERIVATIVES AND THEIR USE FOR TREATING OR PREVENTING VIRAL INFECTIONS | IDO1, IDO2, ZC3HAV1 | PDPK1 3663/4885MKNK2 1656/4885EGFR 2645/4885 |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | PDPK1 3668/4885MKNK2 1385/4885EGFR 2031/4885 |
| US-20110104110-A1 | SUBSTITUTED INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, INMT | PDPK1 3717/4885MKNK2 2056/4885EGFR 2629/4885 |
| US-20110189127-A1 | TRICYCLIC INDOLE DERIVATIVES AND METHODS OF USE THEREOF | IDO1, IDO2, TPH1 | PDPK1 4325/4885MKNK2 1961/4885EGFR 2972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.